We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+117.73%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.51B
AUM Growth
+$863M
Cap. Flow
-$27.8M
Cap. Flow %
-1.11%
Top 10 Hldgs %
46.81%
Holding
87
New
12
Increased
10
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
VIE
Viela Bio, Inc. Common Stock
VIE
+$37.7M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$31.4M
3
ZYME icon
Zymeworks
ZYME
+$25.4M
4
CABA icon
Cabaletta Bio
CABA
+$25.1M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$24.2M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.6M
2
QURE icon
uniQure
QURE
+$27.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$16.1M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.9M
5
ALLK
Allakos
ALLK
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TPTX
1
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$212M 8.44%
3,396,650
-144,717
-4% -$6.89M
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$167M 6.66%
816,400
-3,369
-0.4% -$615K
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$165M 6.59%
1,282,392
-317,608
-20% -$30.6M
CCXI
4
DELISTED
ChemoCentryx, Inc.
CCXI
$115M 4.58%
2,900,000
+1,080,000
+59% +$19M
PRNB
5
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$109M 4.35%
1,990,922
+649,026
+48% +$24.2M
CNST
6
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$108M 4.32%
2,300,000
+1,086,726
+90% +$31.4M
BBIO icon
7
BridgeBio Pharma
BBIO
$16.4B
$88.1M 3.51%
2,512,865
-104,701
-4% -$2.9M
APLS
8
DELISTED
Apellis Pharmaceuticals
APLS
$82.7M 3.3%
2,700,000
-276,000
-9% -$7.64M
MRTX
9
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$64.4M 2.57%
500,000
+300,000
+150% +$28.9M
AXSM icon
10
Axsome Therapeutics
AXSM
$11.7B
$62M 2.47%
+600,000
New +$24.2M
CRSP icon
11
CRISPR Therapeutics
CRSP
$4.69B
$60.9M 2.43%
1,000,000
-84,300
-8% -$4.6M
NXTC icon
12
NextCure
NXTC
$20.4M
$56.3M 2.25%
83,333
+9,616
+13% +$4.82M
ASND icon
13
Ascendis Pharma A/S
ASND
$16.5B
$55.6M 2.22%
400,000
-68,300
-15% -$7.59M
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$54.4M 2.17%
1,000,000
-281,400
-22% -$13.9M
RETA
15
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$51.1M 2.04%
+250,000
New +$45.6M
MYOK
16
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$51M 2.04%
700,000
+257,000
+58% +$15.6M
STOK icon
17
Stoke Therapeutics
STOK
$1.84B
$50.7M 2.02%
1,788,643
+249
+0% +$6.26K
YMAB
18
DELISTED
Y-mAbs Therapeutics
YMAB
$50.1M 2%
1,602,376
+718,576
+81% +$21.3M
XBI icon
19
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$47.6M 1.9%
500,000
+100,000
+25% +$8.65M
RCKT icon
20
Rocket Pharmaceuticals
RCKT
$343M
$41.8M 1.67%
1,837,269
-286,491
-13% -$4.78M
VIE
21
DELISTED
Viela Bio, Inc. Common Stock
VIE
$40.7M 1.62%
+1,497,500
New +$37.7M
TCDA
22
DELISTED
Tricida, Inc. Common Stock
TCDA
$35M 1.4%
927,975
-154,905
-14% -$5.77M
ASND icon
23
CALL
Ascendis Pharma A/S
ASND
$16.5B
$34.8M 1.39%
250,000
– –
AXNX
24
DELISTED
Axonics, Inc. Common Stock
AXNX
$33.9M 1.35%
1,222,671
– –
QTNT
25
DELISTED
Quotient Limited Ordinary Shares
QTNT
$33.3M 1.33%
87,500
-3,550
-4% -$1.18M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Cormorant Asset Management held 87 positions worth $2.51B, up 53% from $1.64B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q4 2019 filing shows 12 new, 10 increased, 29 reduced and 20 closed positions. Its largest new stake was Viela Bio, Inc. Common Stock: 1,497,500 shares worth $40.7M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier.

  • Cormorant Asset Management's largest Q4 2019 buy was Viela Bio, Inc. Common Stock: 1,497,500 shares worth $40.7M.
  • Cormorant Asset Management added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $31.4M increase.
  • Cormorant Asset Management's biggest Q4 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $30.6M.
  • Cormorant Asset Management fully exited Sage Therapeutics in Q4 2019, selling an estimated $12.4M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $2.51B portfolio in Q4 2019.
  • Cormorant Asset Management opened 12 new positions and closed 20 in Q4 2019.
  • Cormorant Asset Management's portfolio value rose 53% quarter-over-quarter to $2.51B.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.